Comparison of topical and intravenous administration of WIN 55-212-2 in normotensive rabbits

Current Eye Research

Volumn 33, Issue 10, 2008, Pages 857-863

  Samudre, Sandeep S ^a   Schneider, Jennifer L ^a   Oltmanns, Matthew H ^a   Hosseini, Alireza ^a   Pratap, Kiran ^a   Loose Thurman, Patricia ^a   Allen, Robert C ^b   Williams, Patricia B ^a   Lattanzio Jr , Frank A ^a   Sheppard Jr , John D ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Intravenous; Rabbits; Tocrisolve ; Topical; WIN 55 212 2

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; TIMOLOL;

ANIMAL EXPERIMENT; ARTICLE; BIOMICROSCOPY; BLOOD PRESSURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG SAFETY; FEMALE; GLAUCOMA; HEART RATE; INTRAOCULAR PRESSURE; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; RABBIT;

ADMINISTRATION, TOPICAL; ANIMALS; BENZOXAZINES; BLOOD PRESSURE; CANNABINOIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART RATE; INJECTIONS, INTRAVENOUS; INTRAOCULAR PRESSURE; MORPHOLINES; NAPHTHALENES; RABBITS; TIMOLOL; TONOMETRY, OCULAR;

EID: 53849095684     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.1080/02713680802419724     Document Type: Article

References (30)

1. Zhang Y, Gao Q, Duan S, et al. Upregulation of Copine1 in trabecular meshwork cells of POAG patients: A membrane proteomics approach. Mol Vis. 2008;14:1028-1036.
2. Chauhan BC. Endothelin and its potential role in glaucoma. Can J Ophthalmol. 2008;43:356-360.
3. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 1998;126:487-497.
4. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol. 2000;130:429-440.
5. Sofia RD, Kubena RK, Barry III H. Comparison among four vehicles and four routes for administering Δ9-tetrahydrocannabinol. J Pharm Sci. 1974;63:939-941.
6. Green K, Roth M. Ocular effects of topical administration of Δ9-tetrahydrocannabinol in man. Arch Ophthalmol. 1982;100:265-267.
7. Juntunen J, Jarvinen T, Niemi R. In vitro corneal permeation of cannabinoids and their water-soluble phosphate ester prodrugs. J Pharm Pharmacol. 2005;57:1153-1157.
8. Pate DW, Jarvinen K, Urtti A, Mahadevan V, Jarvinen T. Effect of the CB1 receptor antagonist, SR141716A, on cannabinoid-induced ocular hypotension in normotensive rabbits. Life Sci. 1998;63:2181-2188.
9. Kearse EC, Green K. Effect of vehicle upon in vitro transcorneal permeability and intracorneal content of Δ9-tetrahydrocannabinol. Curr Eye Res. 2000;20:496-501.
10. Green KE, Kearse CE. Ocular penetration of topical Δ9- tetrahydrocannabinol from rabbit corneal or cul-de-sac application site. Curr Eye Res. 2000;21:566-570.
11. Valiveti S, Hammell DC, Earles DC, Stinchcomb AL. Transdermal delivery of the synthetic cannabinoid WIN 55-212-2: In vitro/in vivo correlation. Pharm Res. 2004;21:1137-1145.
12. Green K, Bigger JF, Kim K, Bowman K. Cannabinoid penetration and chronic effects in the eye. Exp Eye Res. 1977;24:197-205.
13. Green K, Wynn H, Bowman KA. A comparison of topical cannabinoids on intraocular pressure. Exp Eye Res. 1978;27:239-246.
14. Merritt JC, Perry DD, Russell DN, Jones BF. Topical Δ9- tetrahydrocannabinol and aqueous dynamics in glaucoma. J Clin Pharmacol. 1981;21:467S-471S.
15. Colasanti BK, Craig CR, Allara RD. Intraocular pressure, ocular toxicity, and neurotoxicity after administration of cannabinol or cannabigerol. Exp Eye Res. 1984;39:251-259.
16. Muchtar S, Almog S, Torracca MT, Saettone MF, Benita S. A submicron emulsion as ocular vehicle for Δ8-tetrahydrocannabinol: Effect on intraocular pressure in rabbits. Ophthalmic Res. 1992;24:142-149.
17. Friedenwald JS, Buschke W. Some factors concerned in the mitotic and wound-healing activities of the corneal epithelium. Trans Am Ophthalmol Soc. 1944;42:371-383.
18. Samudre SS, Lattanzio FA Jr, Williams PB, Sheppard JD Jr. Comparison of topical steroids for acute anterior uveitis. J Ocul Pharmacol Ther. 2004;20:533-547.
19. Hepler RS, Frank IR. Marihuana smoking and intraocular pressure. JAMA. 1971;217:1392.
20. Wilson DM, Peart J, Martin BR, Bridgen DT, Byron PR, Lichtman AH. Physiochemical and pharmacological characterization of a Δ9-THC aerosol generated by a metered dose inhaler. Drug Alcohol Depend. 2002;67:259-267.
21. Korczyn AD, Eshel Y. Mydriasis induced by tetrahydrocannabinol (THC) in rats. Invest Ophthalmol Vis Sci. 1982;22:408-410.
22. Valiveti S, Hammell DC, Earles DC, Stinchcomb AL. In vitro/in vivo correlation studies for transdermal Δ8-THC development. J Pharm Sci. 2004;93:1154-1164.
23. Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK. Plasma Δ9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther. 1980;28:409-416.
24. Tomida I, Pertwee RG, Azuara-Blanco A. Cannabinoids and glaucoma. Br J Ophthalmol. 2004;88:708-713.
25. Mannila J, Jarvinen T, Jarvinen K, Tervonen J, Jarho P. Sublingual administration of Δ9-tetrahydrocannabinol/beta-cyclodextrin complex increases the bioavailability of Δ9-tetrahydrocannabinol in rabbits. Life Sci. 2006;78:1911-1914.
26. Tomida I, Azuara-Blanco A, House H, Flint M, Pertwee RG, Robson PJ. Effect of sublingual application of cannabinoids on intraocular pressure: A pilot study. J Glaucoma. 2006;15:349-353.
27. Brenneisen R, Egli A, Elsohly MA, Henn V, Spiess Y. The effect of orally and rectally administered Δ9-tetrahydrocannabinol on spasticity: A pilot study with 2 patients. Int J Clin Pharmacol Ther. 1996;34:446-452.
28. Perlin E, Smith CG, Nichols AI, et al. Disposition and bioavailability of various formulations of tetrahydrocannabinol in the rhesus monkey. J Pharm Sci. 1985;74:171-174.
29. Jarho P, Pate DW, Brenneisen R, Jarvinen T. Hydroxypropyl-beta- cyclodextrin and its combination with hydroxypropyl-methylcellulose increases aqueous solubility of Δ9-tetrahydrocannabinol. Life Sci. 1998;63:PL381-384.
30. Hosseini A, Lattanzio FA, Williams PB, Tibbs D, Samudre SS, Allen RC. Chronic topical administration of WIN 55-212-2 maintains a reduction in IOP in a rat glaucoma model without adverse effects. Exp Eye Res. 2006;82:753-759.